At present, several ICIs have been approved by the FDA for the clinical treatment of various cancers, including nivolumab and pembrolizumab for blocking PD-1, atezolizumab and avelumab for blocking PD-L1, and ipilimumab and tremelimumab for blocking CTLA-4 on the cell surface [2]. This evidence concerns the gene PDCD1 and cancer.